229 related articles for article (PubMed ID: 21738965)
1. Adverse cutaneous reactions to epidermal growth factor receptor inhibitors: a study of 14 patients.
Santiago F; Gonçalo M; Reis JP; Figueiredo A
An Bras Dermatol; 2011; 86(3):483-90. PubMed ID: 21738965
[TBL] [Abstract][Full Text] [Related]
2. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions.
Amitay-Laish I; David M; Stemmer SM
Oncologist; 2010; 15(9):1002-8. PubMed ID: 20709888
[TBL] [Abstract][Full Text] [Related]
3. [Cutaneous reactions due to the use of epidermal growth factor receptor inhibitors: two case reports].
Rodarte CM; Abdallah OA; Barbosa NF; Koch Lde O; Resende UM
An Bras Dermatol; 2009; 84(6):667-70. PubMed ID: 20191181
[TBL] [Abstract][Full Text] [Related]
4. [Acneiform eruption from epidermal growth factor receptor inhibitors].
Martínez de Lagrán Z; Ratón JA; Lasa O; Acebo E; Díaz-Pérez JL
Actas Dermosifiliogr; 2005 Sep; 96(7):450-4. PubMed ID: 16476273
[TBL] [Abstract][Full Text] [Related]
5. [Cutaneous side effects of EGF-receptor inhibition and their management].
Gutzmer R; Werfel T; Kapp A; Elsner J
Hautarzt; 2006 Jun; 57(6):509-13. PubMed ID: 16205868
[TBL] [Abstract][Full Text] [Related]
6. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
[TBL] [Abstract][Full Text] [Related]
7. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients.
Roé E; García Muret MP; Marcuello E; Capdevila J; Pallarés C; Alomar A
J Am Acad Dermatol; 2006 Sep; 55(3):429-37. PubMed ID: 16908348
[TBL] [Abstract][Full Text] [Related]
8. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
9. [Cutaneous side effects of EGFR inhibitors--appearance and management].
Wollenberg A; Kroth J; Hauschild A; Dirschka T
Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
[TBL] [Abstract][Full Text] [Related]
10. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.
Segaert S; Tabernero J; Chosidow O; Dirschka T; Elsner J; Mancini L; Maughan T; Morere JF; Santoro A; Sobrero A; Van Cutsem E; Layton A
J Dtsch Dermatol Ges; 2005 Aug; 3(8):599-606. PubMed ID: 16033478
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous adverse events of epidermal growth factor receptor inhibitors: A retrospective review of 99 cases.
Chanprapaph K; Pongcharoen P; Vachiramon V
Indian J Dermatol Venereol Leprol; 2015; 81(5):547. PubMed ID: 25994883
[TBL] [Abstract][Full Text] [Related]
12. Pre-emptive skin toxicity treatment for anti-EGFR drugs: evaluation of efficacy of skin moisturizers and lymecycline. A phase II study.
Grande R; Narducci F; Bianchetti S; Mansueto G; Gemma D; Sperduti I; Trombetta G; Angelini F; Gamucci T
Support Care Cancer; 2013 Jun; 21(6):1691-5. PubMed ID: 23314653
[TBL] [Abstract][Full Text] [Related]
13. [Adverse cutaneous reactions to erlotinib].
Pitarch G; Garde J; Torrijos A; Juárez A; Febrer MI; Camps C
Actas Dermosifiliogr; 2008; 99(1):54-60. PubMed ID: 18206087
[TBL] [Abstract][Full Text] [Related]
14. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
Wu PA; Balagula Y; Lacouture ME; Anadkat MJ
Curr Opin Oncol; 2011 Jul; 23(4):343-51. PubMed ID: 21537180
[TBL] [Abstract][Full Text] [Related]
15. Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer: A Clinicopathologic Study of 32 Cases.
Cho YT; Chen KL; Sheen YS; Yang CW; Liau JY; Cheng YP; Chu CY
JAMA Dermatol; 2017 Sep; 153(9):906-910. PubMed ID: 28538945
[TBL] [Abstract][Full Text] [Related]
16. [Contribution to acneiform eruptions by epidermal growth factor receptor inhibitors].
Bodet D; Bartralot R; Mollet J; Heras C; García-Patos V
Actas Dermosifiliogr; 2006 Mar; 97(2):148-9. PubMed ID: 16595122
[No Abstract] [Full Text] [Related]
17. Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab.
Bragg J; Pomeranz MK
Dermatol Online J; 2007 Jan; 13(1):1. PubMed ID: 17511934
[TBL] [Abstract][Full Text] [Related]
18. [Cutaneous side effects of EGF receptor inhibitors].
Nassar D; Soutou B; Aractingi S
Bull Cancer; 2009 Dec; 96 Suppl():S85-91. PubMed ID: 20034874
[TBL] [Abstract][Full Text] [Related]
19. Targeting the epidermal growth factor receptor in colorectal carcinoma.
Kurtin SE
Cancer Nurs; 2007; 30(4 Suppl 1):S1-9. PubMed ID: 17666985
[TBL] [Abstract][Full Text] [Related]
20. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
